Movement Alert｜Stryker Falls 4.11% in Regular Trading, Q2 Core Segment Revenue Misses and Full-Year Guidance Barely Raised

Market Focus07-31

On July 31, Stryker declined 4.11% in regular trading, trading at $322.21/share, with turnover of $266 million.

The sell-off follows the company's Q2 earnings release on July 30 after market close. While adjusted EPS of $3.69 beat the consensus estimate of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, the MedSurg and Neurotechnology segment — its largest revenue contributor — reported $3.6 billion in sales, missing the $3.72 billion analyst expectation. Despite the strong Q2 EPS beat, the company only narrowed its full-year adjusted EPS guidance from $14.90-$15.10 to $14.95-$15.10, raising concerns over second-half growth sustainability. Additionally, lingering effects from a Q1 cybersecurity incident weighed on investor sentiment. Piper Sandler subsequently lowered its price target from $420 to $390, maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144176828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 21:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144176828","market":"us","top_or_hot":-1,"title":"Movement Alert｜Stryker Falls 4.11% in Regular Trading, Q2 Core Segment Revenue Misses and Full-Year Guidance Barely Raised","media":"Market Focus","content":"<p><p>On July 31, Stryker declined 4.11% in regular trading, trading at $322.21/share, with turnover of $266 million.</p><p>The sell-off follows the company's Q2 earnings release on July 30 after market close. While adjusted EPS of $3.69 beat the consensus estimate of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, the MedSurg and Neurotechnology segment — its largest revenue contributor — reported $3.6 billion in sales, missing the $3.72 billion analyst expectation. Despite the strong Q2 EPS beat, the company only narrowed its full-year adjusted EPS guidance from $14.90-$15.10 to $14.95-$15.10, raising concerns over second-half growth sustainability. Additionally, lingering effects from a Q1 cybersecurity incident weighed on investor sentiment. Piper Sandler subsequently lowered its price target from $420 to $390, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Stryker Falls 4.11% in Regular Trading, Q2 Core Segment Revenue Misses and Full-Year Guidance Barely Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Stryker Falls 4.11% in Regular Trading, Q2 Core Segment Revenue Misses and Full-Year Guidance Barely Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Stryker declined 4.11% in regular trading, trading at $322.21/share, with turnover of $266 million.</p><p>The sell-off follows the company's Q2 earnings release on July 30 after market close. While adjusted EPS of $3.69 beat the consensus estimate of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, the MedSurg and Neurotechnology segment — its largest revenue contributor — reported $3.6 billion in sales, missing the $3.72 billion analyst expectation. Despite the strong Q2 EPS beat, the company only narrowed its full-year adjusted EPS guidance from $14.90-$15.10 to $14.95-$15.10, raising concerns over second-half growth sustainability. Additionally, lingering effects from a Q1 cybersecurity incident weighed on investor sentiment. Piper Sandler subsequently lowered its price target from $420 to $390, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYK","symbol_name":"史赛克","start_time":0,"source_url":"","article_id":"1144176828","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144176828","pubTimestamp":1785505788,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Stryker declined 4.11% in regular trading, trading at $322.21/share, with turnover of $266 million.The sell-off follows the company's Q2 earnings release on July 30 after market close....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYK":"史赛克"},"translate_title":"走势警报|史赛克常规交易下跌 4.11%，第二季度核心部门收入未达预期，全年指引几乎没有上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1},"content_text":"On July 31, Stryker declined 4.11% in regular trading, trading at $322.21/share, with turnover of $266 million.The sell-off follows the company's Q2 earnings release on July 30 after market close. While adjusted EPS of $3.69 beat the consensus estimate of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, the MedSurg and Neurotechnology segment — its largest revenue contributor — reported $3.6 billion in sales, missing the $3.72 billion analyst expectation. Despite the strong Q2 EPS beat, the company only narrowed its full-year adjusted EPS guidance from $14.90-$15.10 to $14.95-$15.10, raising concerns over second-half growth sustainability. Additionally, lingering effects from a Q1 cybersecurity incident weighed on investor sentiment. Piper Sandler subsequently lowered its price target from $420 to $390, maintaining an Overweight rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144176828","isCrawlerRequest":true}